Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 54 |
| Active Pipeline (Recruiting Now) | 37 (17) |
| Completed vs Stopped Early | 4 / 0 (0.0%) |
| Median Closed Actual Enrollment | 38 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei | 17 |
| Tianjin Medical University General Hospital | Tianjin, Tianjin Municipality | 3 |
| Xiangya Hospital Central South University | Changsha, Hunan | 2 |
Explore interactive annual charts and M&A subsidiary rollups in the Tongji Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.